Bridges Investment Management Inc. Buys 13,439 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bridges Investment Management Inc. lifted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 111.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,509 shares of the medical equipment provider's stock after purchasing an additional 13,439 shares during the period. Bridges Investment Management Inc.'s holdings in Lantheus were worth $2,490,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Janus Henderson Group PLC boosted its holdings in shares of Lantheus by 72.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after acquiring an additional 2,610,118 shares during the period. Farallon Capital Management LLC boosted its holdings in Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after purchasing an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. boosted its stake in shares of Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after buying an additional 435,445 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Lantheus by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock worth $120,510,000 after purchasing an additional 30,891 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC grew its stake in Lantheus by 39.1% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider's stock worth $87,124,000 after buying an additional 273,838 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares in the company, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.00% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Truist Financial lowered their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, B. Riley lowered their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $131.20.

Lantheus Trading Down 3.0%

Shares of LNTH stock traded down $2.52 during trading hours on Friday, hitting $81.31. 816,768 shares of the company were exchanged, compared to its average volume of 975,278. Lantheus Holdings, Inc. has a fifty-two week low of $73.11 and a fifty-two week high of $126.89. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74. The firm has a market cap of $5.63 billion, a P/E ratio of 23.10 and a beta of 0.12. The company has a 50 day simple moving average of $80.26 and a two-hundred day simple moving average of $89.91.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The company had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. During the same period last year, the company earned $1.69 EPS. Lantheus's revenue for the quarter was up .8% compared to the same quarter last year. Equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.